Sangamo Therapeutics (SGMO) Tops Q1 EPS by 1c

Sangamo Therapeutics (NASDAQ: SGMO) reported Q1 EPS of ($0.30), $0.01 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $28.2 million versus the consensus estimate of $27.29 million.

For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Beike (BEKE) PT Raised to $23 at Morgan Stanley
• Ross Stores, Inc. (ROST) PT Raised to $240 at Bernstein SocGen Group